The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), received a $725,420 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The project aims to develop and validate an optimized positron emission tomography (PET) probe to non-invasively detect and quantify renal fibrosis, a key driver of chronic kidney disease progression. The 5-year award will support further preclinical studies, including radiation dosimetry estimation, Good Laboratory Practice (GLP) toxicology testing, and establishing a Good Manufacturing Practice (GMP) manufacturing process for the PET probe. Successful completion of this project will position the research team to conduct subsequent human clinical trials to evaluate the probe's utility in kidney disease diagnosis and monitoring therapeutic response.
Generated 2/25/25, 4:53 AM